Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EUSA Pharma

www.eusapharma.com

Latest From EUSA Pharma

Tivozanib Non-Oncology Buy-Back Gives Quick Cash To AVEO

In a move that will generate further useful cash for AVEO, Kyowa Kirin has reacquired global rights to non-oncology uses of tivozanib.

Business Strategies Commercial

Aveo's Tivozanib Under CHMP Spotlight If Negative OS Trend Continues In TIVO-3

An August 2019 analysis of overall survival in the TIVO-3 study of Aveo’s tivozanib in advanced renal cell carcinoma is now an interim rather than a final analysis, but EU regulators may take action if a negative overall survival trend is found to be continuing.

 

Cancer Clinical Trials

Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier

Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.

Deals Business Strategies

EUSA Sylvant Licence Marks Toehold Into US Rare Disease Market

Six months after selling its critical care business to refocus on rare diseases and oncology, EUSA Pharma has made its first move into those markets by licensing a Janssen product for a rare blood disorder.

Rare Diseases Deals
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Dental & Oral Products
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Poison (Antidote)
  • Alias(es)
  • Essex Bidco Ltd.
  • EUSA Pharma Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • EUSA Pharma
  • Senior Management
  • Lee Morley, CEO
    Emma Johnson, CFO
    Jonathan Morgan, Med. Dir.
    Ben Owens, Head, Bus. Dev.
  • Contact Info
  • EUSA Pharma
    Phone: 3305001140
    Breakspear Park, Breakspear Way, Gr. Fl.
    Ste. GE
    Hemel Hempstead, PA HP2 4TZ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register